Cannabis has been used for therapeutic purposes for more than 4,000 years. Multiple studies have been conducted around the world that have investigated and highlighted the numerous medicinal benefits of this plant. Within professional medical fields, the treatment of illnesses with cannabis derivatives has spread.
Some of the most widespread beneficial applications of cannabis-based medications include:
- reducing epileptic seizures,
- slowing the growth of cancer,
- reducing pain and vomiting in chemotherapy treatments,
- slowing the progression of Alzheimer’s disease,
- and relieving the pain of multiple sclerosis, among others.
The innovative merit of the project is the procurement of cannabis oils, which contain a sought-after mix of cannabinoids for the treatment of various diseases, by means of a combination of proper procedures for seed selection, plant production and standardized extraction processes.
The company is lead by two founding partners: Sergio Merofa y João Paulo Rocha, both from Brazil. Providing technical support is Master of Molecular Biology and Ph.D in Neuroscience Dr. Renato Malcher. The technical and scientific lead (lead scientific technician) of the project is Eleonora Scosería, owner of Infodynamis, who brings vast experience in the national pharmaceutical sector.
For conducting and carrying out research and development activities, the services of the chemistry department at Pando Technology Park have been secured, providing advice and technical support.
For the development and start-up of the business, the company is in the midst of the construction of its own production plant, which will be inaugurated in 2018 (laboratories, offices, cultivation rooms, etc.) located within the Pando Technology Park.
The medicinal use of cannabis is an issue currently on the agenda for most countries in the world.
Latin America is no exception, as governments in the region are debating the legalization of production and the specific uses of the plant. By February 2018, medicinal use will be regulated and permitted for most countries in the region, and there are already hundreds of cases where cannabis extracts have been imported for compassionate medicinal use.
Currently, cannabis extracts with the characteristics to be produced by GrüneLabs are not available in the local and regional market, nor are the production processes that ensure Pharma-Grade level quality.